Clinical Trial Update: A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating ustekinumab (Stelara) in Chinese participants with moderately to severely active Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn Disease | Phase 4 | Status: COMPLETED